AMAG Pharmaceuticals Inc. (AMAG) Rating Reiterated by Leerink Swann
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)‘s stock had its “outperform” rating restated by equities research analysts at Leerink Swann in a research note issued to investors on Thursday. They presently have a $36.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s price objective points to a potential upside of 47.18% from the company’s previous close.
Several other brokerages have also issued reports on AMAG. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 5th. Jefferies Group decreased their price target on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research note on Wednesday, August 10th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $36.33.
AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 5.48% during mid-day trading on Thursday, hitting $24.46. The company’s stock had a trading volume of 582,990 shares. The firm has a 50 day moving average of $24.07 and a 200-day moving average of $23.92. AMAG Pharmaceuticals has a 52-week low of $17.92 and a 52-week high of $42.49. The firm’s market cap is $835.41 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/amag-pharmaceuticals-inc-amag-rating-reiterated-by-leerink-swann.html
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.20 by $0.25. The firm earned $127.40 million during the quarter, compared to analyst estimates of $128.52 million. AMAG Pharmaceuticals had a negative net margin of 4.87% and a positive return on equity of 13.98%. The company’s revenue for the quarter was up 46.7% on a year-over-year basis. During the same quarter last year, the business posted $1.12 EPS. On average, equities research analysts expect that AMAG Pharmaceuticals will post $5.55 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Texas Permanent School Fund purchased a new position in shares of AMAG Pharmaceuticals during the first quarter worth about $650,000. Virginia Retirement System purchased a new position in shares of AMAG Pharmaceuticals during the first quarter worth about $402,000. Teachers Advisors Inc. increased its position in shares of AMAG Pharmaceuticals by 0.6% in the first quarter. Teachers Advisors Inc. now owns 211,501 shares of the specialty pharmaceutical company’s stock worth $4,949,000 after buying an additional 1,303 shares during the last quarter. Prudential Financial Inc. purchased a new position in shares of AMAG Pharmaceuticals during the first quarter worth about $5,563,000. Finally, BlackRock Inc. increased its position in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,615 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.